Additional Prescription Drug Coverage Updates Taking Effect January 1, 2021

In addition to those announced in the November 18 issue of NRECA Employee Benefits Weekly, the following changes to NRECA’s Medical Plan prescription drug coverage will take effect on January 1, 2021:

• Removed from the formulary: DUEXIS, VIMOVO, 510k topical dermatological products (e.g., BEAU RX, RECEDO, CELACYN), 510k artificial saliva products (e.g., NEUTRASAL, SALIVAMAX, SALIVATE)
• Prior authorization will be required: SOLARAZE, Transmucosal immediate-release fentanyl (TIRF) medications, VFEND, as well as prescription dietary supplements, multivitamins and probiotics (e.g. PRODIGEN, NOXIFOL-D)
• A quantity limit with prior authorization will be required: Podiatry foot bath products (e.g., ECONAZOLE, CICLOPIROX), topical corticosteroid medications

Letters have been mailed to affected participants notifying them of these changes.

Participants can visit the Manage Your Prescriptions page on the Employee Benefits website to check on coverage and costs on prescription drugs. Use the Check Drug Cost & Coverage link under Plans & Benefits.

If you or your participants have questions about prescription drug coverage or about these updates, call CVS Caremark Customer Care at 888.796.7322.